Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Nov 26, 2024

SELL
$1.19 - $2.19 $341,530 - $628,530
-287,000 Closed
0 $0
Q4 2022

Nov 26, 2024

SELL
$1.07 - $1.34 $307,090 - $384,580
-287,000 Closed
0 $0
Q3 2022

Nov 26, 2024

BUY
$1.09 - $1.67 $312,830 - $479,290
287,000 New
287,000 $316 Million
Q2 2022

Nov 26, 2024

SELL
$1.13 - $3.69 $55,369 - $180,810
-49,000 Reduced 14.58%
287,000 $522 Million
Q1 2022

Nov 22, 2024

BUY
$2.85 - $3.73 $253,650 - $331,970
89,000 Added 44.95%
287,000 $936 Million
Q4 2021

Nov 22, 2024

BUY
$3.24 - $5.18 $641,520 - $1.03 Million
198,000 New
198,000 $655 Million
Q1 2021

Nov 22, 2024

BUY
$5.03 - $8.8 $201,200 - $352,000
40,000 Added 25.32%
198,000 $1.26 Billion
Q3 2020

Nov 22, 2024

BUY
$3.64 - $7.76 $575,120 - $1.23 Million
158,000 New
158,000 $638 Million
Q2 2020

Nov 22, 2024

SELL
$4.78 - $8.26 $4.13 Million - $7.14 Million
-864,000 Reduced 84.54%
158,000 $1.06 Billion
Q1 2020

Nov 22, 2024

SELL
$4.0 - $21.53 $6.47 Million - $34.8 Million
-1,618,000 Reduced 61.29%
1,022,000 $13.2 Billion
Q4 2019

Nov 22, 2024

BUY
$13.94 - $24.12 $36.8 Million - $63.7 Million
2,640,000 New
2,640,000 $55.9 Billion
Q3 2019

Nov 22, 2024

BUY
$13.89 - $23.16 $527,820 - $880,080
38,000 Added 1.42%
2,708,500 $41.1 Billion
Q2 2019

Nov 22, 2024

BUY
$16.27 - $20.51 $7.39 Million - $9.32 Million
454,500 Added 20.51%
2,670,500 $51.3 Billion
Q1 2019

Nov 22, 2024

BUY
$12.61 - $22.33 $27.9 Million - $49.5 Million
2,216,000 New
2,216,000 $44.4 Billion
Q4 2018

Nov 26, 2024

BUY
$12.41 - $22.98 $4.17 Million - $7.72 Million
336,000 New
336,000 $4.57 Billion

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $202M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.